Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Lexicon Pharmaceuticals

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

IDEAYA Biosciences (NASDAQ:IDYA) has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate the efficacy and safety of IDE397 with Amgen's AMG 193 in a Phase 1 clinical trial. IDEAYA shares traded in a range of $14.59 to $15.82 on a day volume of 130.58…

12 Health Care Stocks Moving In Wednesday's After-Market Session

12 Health Care Stocks Moving In Wednesday's After-Market Session

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Tuesday's Intraday Session

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Lexicon Shares Jump 20 Percent Following Positive Results From Mid-Stage Diabetic Neuropathy Study

Lexicon Pharmaceuticals (NASDAQ: LXRX) reported positive topline results from the Phase 2 proof-of-concept study of its lead candidate LX9211 in painful diabetic neuropathy. The RELIEF-DPN-1 is the first of two Phase 2 proof-of-concept study designed to evaluate LX9211 in patients with neuropathic pain.

Lexicon Pharmaceuticals: Q1 Earnings Insights

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported its Q1 earnings results on Thursday, May 5, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Organisations

Food and Drug Administration

European Medicines Agency

US Food and Drug Administration

IDEAYA Biosciences

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play